HolderBook

STEMPOINT CAPITAL LP

Reported holdings as of Q2 2026, from 11 quarterly filings.

This filer last reported in Q2 2026; the most recent quarter on file across all filers is Q3 2026. Firms that restructure stop filing under one CIK and start under another, so a successor entity may hold these positions now under a similar name.

CIK
1952142
Reported value
$580.5M
Positions
77
Top 10 weight
41.1%
Filed
2026-08-14
Days after quarter end
45

Holdings

Download these holdings as CSV

SecurityTickerValue SharesWeightWeight change Held Change
TANGO THERAPEUTICS INC CALLTNGX$38.4M1,223,0196.62%+5.81pp2q+204.4%+$25.8M
ABIVAX SAABVX$37.8M283,6576.51%-0.23pp5q-54.8%-$45.8M
REVOLUTION MEDICINES INC PUTRVMD$30.1M159,9435.18%-0.20pp4q-71.6%-$75.9M
ERASCA INC PUTERAS$28.8M1,565,9134.96%+4.21pp2q+226.4%+$20.0M
TYRA BIOSCIENCES INCTYRA$20.2M632,7543.48%+2.00pp2q+63.8%+$7.9M
DIANTHUS THERAPEUTICS INCDNTH$19.6M200,8513.37%+1.99pp4q+17.5%+$2.9M
ENLIVEN THERAPEUTICS INCELVN$17.6M346,9143.03%+0.28pp2q-52.3%-$19.3M
BIOHAVEN LTD CALLBHVN$16.4M1,064,2002.82%+0.22pp2q-66.6%-$32.7M
MINERALYS THERAPEUTICS INCMLYS$16.3M602,6862.80%+0.01pp7q-43.5%-$12.5M
SURROZEN INCSRZN$13.8M602,7982.37%+0.53pp9q-16.5%-$2.7M
KINIKSA PHARMACEUTICALS INTLKNSA$13.4M209,2342.30%-newNEW
SCHOLAR ROCK HLDG CORPSRRK$13.2M239,1462.27%-7.67pp7q-88.5%-$100.8M
ALKERMES PLCALKS$13.0M248,0152.24%+1.69pp2q+54.1%+$4.6M
FIRST TRACKS BIOTHERAPEUTICSTRAX$12.5M622,7232.16%-newNEW
PRAXIS PRECISION MEDICINES IPRAX$12.5M37,2432.15%-1.35pp3q-66.9%-$25.2M
ROIVANT SCIENCES LTD PUTROIV$12.4M348,4082.13%+0.07pp11q-54.8%-$15.0M
BIOAGE LABS INCBIOA$11.4M464,1711.96%+0.82pp2q-31.5%-$5.2M
CG ONCOLOGY INCCGON$11.3M159,3491.95%-0.73pp2q-61.3%-$17.9M
ORUKA THERAPEUTICS INCORKA$11.1M116,4611.91%-newNEW
IMMUNOVANT INCIMVT$10.7M276,5271.84%-1.79pp11q-81.5%-$46.9M
CELCUITY INCCELC$10.3M98,2031.77%+0.45pp4q-18.2%-$2.3M
RELMADA THERAPEUTICS INCRLMD$10.1M1,460,0931.74%+0.94pp2q+22.2%+$1.8M
CLIMB BIO INCCLYM$9.7M742,7451.67%-newNEW
SPYRE THERAPEUTICS INCSYRE$9.5M106,9261.64%flat3q-68.1%-$20.3M
ZURA BIO LTDZURA$8.1M1,368,2151.39%+0.53pp2q-9.2%-$819.1K
INFLARX NVIFRX$7.2M3,228,2551.25%-newNEW
AMYLYX PHARMACEUTICALS INCAMLX$6.9M384,3041.19%-0.61pp4q-71.3%-$17.2M
CELLDEX THERAPEUTICS INC NEWCLDX$6.6M178,4121.14%-0.41pp2q-64.9%-$12.3M
OVID THERAPEUTICS INCOVID$6.5M2,417,2831.12%-newNEW
EQUILLIUM INCEQ$6.5M2,016,6071.11%-newNEW
DEFINIUM THERAPEUTICS INCDFTX$6.5M137,1241.11%-0.08pp2q-78.9%-$24.2M
CYTOKINETICS INCCYTK$6.4M75,6031.11%-0.54pp3q-70.8%-$15.6M
DAMORA THERAPEUTICS INCDMRA$5.6M216,1940.97%-newNEW
INVENTIVA SAIVA$5.4M1,426,3200.93%-newNEW
CENTURY THERAPEUTICS INCIPSC$5.3M2,146,1820.91%-newNEW
AURA BIOSCIENCES INCAURA$5.1M714,2800.87%-newNEW
EYEPOINT INCEYPT$4.8M338,4710.83%-1.18pp3q-79.1%-$18.3M
ASSEMBLY BIOSCIENCES INCASMB$4.7M170,3780.81%-0.19pp4q-54.1%-$5.5M
WHITEHAWK THERAPEUTICS INCWHWK$4.7M1,021,0370.81%+0.18pp4q-45.7%-$3.9M
XENON PHARMACEUTICALS INCXENE$4.6M76,0750.79%-0.79pp4q-73.0%-$12.4M
PERSONALIS INC CALLPSNL$4.1M247,7830.71%-newNEW
UNIQURE NVQURE$4.1M88,1150.70%+0.45pp7q-43.6%-$3.1M
COMPASS PATHWAYS PLCCMPS$4.0M284,7690.69%-newNEW
AVALYN PHARMACEUTICALS INCAVLN$3.9M118,0000.67%-newNEW
MAPLIGHT THERAPEUTICS INCMPLT$3.8M106,9060.66%+0.27pp3q-46.5%-$3.3M
ALUMIS INCALMS$3.8M135,7360.66%-0.32pp2q-70.4%-$9.1M
AXSOME THERAPEUTICS INCAXSM$3.8M15,3750.65%-newNEW
MONTE ROSA THERAPEUTICS INCGLUE$3.7M153,5440.64%-newNEW
ACADIA PHARMACEUTICALS INCACAD$3.6M143,1670.62%-0.42pp2q-70.5%-$8.7M
SOLID BIOSCIENCES INCSLDB$3.6M358,7800.62%+0.35pp2q-8.2%-$319.9K
CRESCENT BIOPHARMA INC.CBIO$3.3M182,3820.57%-newNEW
ARROWHEAD PHARMACEUTICALS INARWR$3.2M39,1980.55%-newNEW
KODIAK SCIENCES INCKOD$3.0M75,8720.51%-newNEW
PHARVARIS N VPHVS$2.8M80,9070.48%+0.01pp3q-53.3%-$3.2M
MONOPAR THERAPEUTICS INCMNPR$2.8M30,1250.48%-newNEW
RAPPORT THERAPEUTICS INCRAPP$2.8M66,5820.48%-newNEW
NEWAMSTERDAM PHARMA COMPANYNAMS$2.6M77,5890.45%-0.66pp6q-78.5%-$9.6M
SIONNA THERAPEUTICS INCSION$2.6M59,4260.45%+0.17pp2q-18.7%-$600.6K
ARCUTIS BIOTHERAPEUTICS INCARQT$2.6M98,9450.45%-1.43pp11q-88.0%-$19.1M
C4 THERAPEUTICS INCCCCC$2.4M523,6480.42%+0.19pp2q-42.2%-$1.8M
SPRUCE BIOSCIENCES INCSPRB$2.2M41,3880.38%+0.30pp2q+225.4%+$1.5M
CUE BIOPHARMA INCCUE$2.1M66,9950.36%-newNEW
STRUCTURE THERAPEUTICS INCGPCR$2.0M38,1780.35%-1.51pp4q-90.5%-$19.4M
PROTAGONIST THERAPEUTICS INCPTGX$2.0M16,3030.34%-1.13pp7q-88.8%-$15.8M
HELIX ACQUISITION CORP IIIHLXC$1.8M171,6710.31%-0.28pp2q-71.9%-$4.7M
BIODESIX INCBDSX$1.6M70,0000.27%+0.08pp2q-50.0%-$1.6M
TENAX THERAPEUTICS INCTENX$1.4M96,2730.24%-0.34pp2q-74.5%-$4.1M
SAB BIOTHERAPEUTICS INCSABS$1.3M342,6310.23%-0.05pp3q-54.3%-$1.6M
CALCIMEDICA INCCALC$1.2M1,244,8640.21%-newNEW
LB PHARMACEUTICALS INCLBRX$1.0M31,7850.18%-0.06pp2q-68.2%-$2.2M
CELLECTAR BIOSCIENCES INCCLRB$986.7K354,9380.17%-newNEW
PROQR THRAPEUTICS N VPRQR$801.8K431,0540.14%-newNEW
SPDR SERIES TRUST CALL+PUTXBI$578.0Koptions only0.10%+0.07pp2qOPTIONS
ASTRAZENECA PLC CALLAZN$180.0Koptions only0.03%-newOPTIONS
ARK ETF TR PUTARKG$75.0Koptions only0.01%-newOPTIONS
VISTAGEN THERAPEUTICS INCVTGN$17.3K616,7490.00%-0.01pp11q-50.0%-$17.3K
AMGEN INC PUTAMGN$15.0Koptions only0.00%-newOPTIONS

By sector

Industry comes from the SIC code on each company's own SEC filings, which is self-reported and sometimes out of date. Derivative exposure is counted with the shares. Securities the SEC assigns no industry - funds, trusts, foreign issues - are shown as not classified rather than dropped.

Biotech & Pharma 94.0%Healthcare Services 2.8%Other sectors 0.3%Not classified 2.9%
 
SectorValueShare
Biotech & Pharma$545.6M94.0%
Healthcare Services$16.0M2.8%
Other sectors$1.8M0.3%
Not classified$17.1M2.9%

What the disclosed book did

This is not the fund's return. A 13F shows long US equity positions only, so shorts, bonds, foreign listings, private holdings and cash are all invisible here. What this measures is the quarter's change in value of the positions this manager disclosed, had they been left untouched - the return a reader following the filing would have earned.

QuarterBookMarket DifferencePriced
Q2 2026+25.2%+14.8%+10.4%100%
Q1 2026+8.2%-4.6%+12.8%100%
Q4 2025+26.9%+2.4%+24.6%99%
Q3 2025+48.4%+7.8%+40.6%99%
Q2 2025+1.1%+10.5%-9.4%100%
Q1 2025-16.1%-4.6%-11.5%100%
Q4 2024-13.8%+2.1%-16.0%100%
Q3 2024+6.0%+5.4%+0.6%100%

Market is SPY over the same two quarter ends, priced the same way as everything else here - the median across every filer reporting it. It is a large-cap US proxy, so a manager holding small caps or biotech will beat or trail it for reasons that are not skill. Prices are quarter-end to quarter-end and say nothing about the path in between, or about trades opened and closed inside a quarter.

Quarter by quarter

QuarterValuePositions NewAddedTrimmed ExitedTop 10 Days to file
Q2 2026$580.5M77287412741.1%45
Q1 2026$1.0B76373453645.8%45
Q4 2025$583.2M753227163745.7%48
Q3 2025$499.1M804318171351.3%45
Q2 2025$311.6M501716142450.1%45
Q1 2025$313.7M572812152250.5%45
Q4 2024$400.6M51251862450.8%45
Q3 2024$334.0M502110141356.2%44
Q2 2024$340.3M421614102455.4%44
Q1 2024$378.3M502216103557.9%131
Q4 2023$374.8M63000039.6%44

Rows marked UNVERIFIED ID, PLACEHOLDER ID, TICKER AS ID or NON-CUSIP ID carry an identifier that is not a valid CUSIP. They are shown because the filer reported that money, but treat the security named with caution - hover the chip for what is wrong with it, and see the methodology.

Held counts consecutive filings in which this manager reported the position, and can reach further back than the quarters listed above: the tabs begin at Q4 2018 because earlier coverage is too sparse to describe a market, but tenure is counted over every filing we hold, some reaching to 2007. A position sold and later rebought starts again from one.

Weight change is the shift in this position's share of the whole book, in percentage points. It is the more useful column: when money flows into or out of a broad fund, almost every holding is bought or sold at once, so added and trimmed largely track flows. A weight that rose while the book shrank is a decision. Both compare with the previous quarter this filer reported, not the previous calendar quarter.